A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael Boyle(Royal College of Surgeons in Ireland), David M. Rodman(Miragen Therapeutics (United States)), Michael W. Konstan(Roche (Switzerland)), Scott C. Bell(Douglas Mental Health University Institute), Susanna A. McColley, Xiaohong Huang(Vertex Pharmaceuticals (United States)), David Waltz(Vertex Pharmaceuticals (United States)), Steven M. Rowe(University of Alabama at Birmingham), Ernst Rietschel(University of Cologne), Naimish Patel(Sanofi (United States))
Cited by 442
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k